Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 6/20 | 0.33 |
| ▸ | AKT2 | P31751 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503599 | 0.83 | MEN1 (0.44) | MEN1KMT2AHASPINAKT1AKT2 | |
| SCHEMBL6074658 | 0.83 | MEN1 (0.44) | MEN1KMT2AHASPINAKT1AKT2 | |
| SCHEMBL6073526 | 0.81 | FGFR1 (0.42) | MEN1KMT2AFGFR1SRCHASPIN | |
| SCHEMBL6073344 | 0.80 | FGFR1 (0.40) | MEN1KMT2AFGFR1SRCHASPIN | |
| SCHEMBL6073568 | 0.80 | HASPIN (0.38) | MEN1KMT2AFGFR1SRCHASPIN | |
| SCHEMBL29742257 | 0.80 | FGFR1 (0.40) | MEN1KMT2AFGFR1SRCHASPIN | |
| SCHEMBL1167993 | 0.80 | FGFR1 (0.69) | FGFR1SRC | |
| SCHEMBL5133031 | 0.79 | FGFR1 (0.44) | MEN1KMT2AFGFR1SRCHASPIN | |
| SCHEMBL22057624 | 0.78 | KMT2A (0.53) | MEN1KMT2AHASPINSMN1; SMN2KDM4E | |
| SCHEMBL30078183 | 0.77 | FGFR1 (0.51) | FGFR1SRCHASPINAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | MEN1 4150/4885KMT2A 736/4885FGFR1 1387/4885 |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | MEN1 4797/4885KMT2A 2672/4885FGFR1 280/4885 |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | MEN1 3502/4885KMT2A 4641/4885FGFR1 1070/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | MEN1 3502/4885KMT2A 4641/4885FGFR1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.